Our team has 80+ years of combined experience utilizing ophthalmic animal models for drug development. We specialize in preclinical ophthalmic studies of pharmacology/efficacy, PK/tox, and eyedrop formulation development. Efficacy models include dry eye, allergic conjunctivitis, laser-induced choroidal neovascularization, STZ-induced diabetes, ischemia/reperfusion, inherited retinal degenerations, optic nerve crush, light-induced retinal degeneration, geographic atrophy, retinal vascular leakage, Oxygen-induced retinopathy, corneal neovascularization, glaucoma, experimental autoimmune uveitis, and LC-MS quantification of A2E.Propietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop). This patented technology platform can produce stable and safe formulations that deliver large amounts of drug into the eye.